Navigation Links
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Date:5/29/2008

INDIANAPOLIS, May 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a new indication for Cymbalta(R) (duloxetine HCl) for the management of chronic pain, the company announced today. The submission is based on outcomes of clinical trials in chronic osteoarthritis pain of the knee and chronic low back pain, in addition to data from previously completed pain studies in diabetic peripheral neuropathic pain (DPNP) and fibromyalgia. Cymbalta was studied in chronic pain of at least moderate severity in adults who required daily treatment for an extended period of time.

According to the International Association for the Study of Pain (IASP), pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.(i) Chronic pain persists beyond acute pain or beyond the expected time for an injury to heal.(ii)

About Cymbalta

Serotonin and norepinephrine in the brain and spinal cord are believed to both mediate core mood symptoms and help regulate the perception of pain. Based on pre-clinical studies, Cymbalta is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord). While the mechanism of action of Cymbalta is not fully known, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Cymbalta is approved in the United States for the
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
(Date:7/25/2014)... HILL, N.C. , July 25, 2014  Corporate ... challenges, including understanding new advancements in technology and how ... of this, libraries in the pharmaceutical and medical device ... value of the information and services they provide. ... Best Practices, LLC there are many forces of change ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Forces of Change Reshaping Corporate Libraries & Information Services 2
... on 01/05/2012 of Santa Barbara physician Dr. Julio Diaz ... overdose deaths from prescription medications. According to one of ... centers, Dr. Diaz,s arrest points to the dangers both ... of finding a physician who will prescribe medication for ...
... PHILADELPHIA, January 10, 2012 Shire plc (LSE: ... company, announced today that it has acquired the rights to ... States (US) in an agreement  with Janssen Pharmaceutica N.V.  Terms ... a prokinetic, is part of Shire,s gastrointestinal (GI) portfolio in ...
Cached Medicine Technology:Arrest of California Doctor Coincides with Uptick in Prescription Drug Overdoses 2Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4
(Date:7/28/2014)... researchers in Taiwan has developed a new optical technology ... of diabetes sooner, when it is more easily treated. ... trials, it may pave the way for the early ... diabetic autonomic neuropathy, which is common among people with ... progressively affects the autonomic nerves controlling vital organs like ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Top Northridge ... coupon for new patients. Finding a new dentist can be ... dental issues that have gone untreated and worry about how ... Ariz specializes in patients with special concerns and dental needs ... comfortable and right at home. This special coupon can help ...
(Date:7/28/2014)... July 28, 2014 "I injured my shoulder ... said an inventor from Sunnyvale, Calif. "When I slept in ... the market are cumbersome and require too many straps. That ... developed the Multiple Functioning Vest to improve the design of ... so that they heal properly. This helps to speed up ...
(Date:7/28/2014)... HealthDay Reporter FRIDAY, July ... health insurance this year will face fines of up to ... the Internal Revenue Service says. The Obama administration on ... that some Americans will owe for failing to have health ... monthly national average premium for a bronze-level health plan. ...
(Date:7/28/2014)... 2014 Glidewell Laboratories announced today that ... successfully passed the five-year mark in clinical usage, and ... units prescribed by US dentists. , Even as BruxZir ... good results from respected clinical studies, many dentists expressed ... over extended years of clinical service before they would ...
Breaking Medicine News(10 mins):Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:IRS Caps Fines on Uninsured Americans at $12K for Family of 5 2Health News:BruxZir® Solid Zirconia Surpasses Five Years of Clinical Use 2
... , HARRISBURG, Pa. , Jan. 13 ... launch of an innovative initiative to create clinically proven, ... of care for patients.  The P4 Pathways Program will ... for the treatment of patients with cancer, as well ...
... , NEW YORK , Jan. 13 ... been named president and CEO of Siemens Corporation. Spiegel, an ... on January 18 . , (Logo:   http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ... Senior Partner at Booz & Co. and brings more than ...
... Bradley C. Brennecke , a resident of Pleasant Plain, Ohio ... , pleaded guilty late Tuesday to conspiracy and tax evasion charges before District ... Department and Internal Revenue Service (IRS) announced. , Mrusek and Brennecke, who ... icted in July 2009 and charged with tax ...
... in the general population use the drug responsibly, study finds ... taking Viagra will lead to sexually risky behavior can relax: ... make men more likely to engage in potentially unhealthy sex. ... a doctor who may worry that prescribing erectile-dysfunction drugs to ...
... say researchers working with mice , WEDNESDAY, Jan. 13 ... greater understanding of how a brain becomes susceptible to ... some people are resistant to antidepressants. , Scientists think ... -- cause the mental disorders. Antidepressants (such as Prozac) ...
... aged 6-19 still climbing, government study finds , WEDNESDAY, Jan. ... on weight: Obesity in the United States may finally be ... the rates of obesity remain high, with about one-third of ... obesity among already heavy 6- to 19-year-old boys appear to ...
Cached Medicine News:Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 2Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 3Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 4Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 2Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 3Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News:Taking Viagra Won't Spur Risky Sexual Behavior 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3
Duckbill. 3.5 mm tip. Light curve....
4 mm x 9 mm tip....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. 35 mm from angle to tip....
Medicine Products: